​

Oramed Pharmaceuticals (ORMP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ORMP Stock Rating

Oramed Pharmaceuticals stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (75.00%), 2 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 6 Strong Sell Sell Hold Buy Strong Buy

ORMP Price Target Upside V Benchmarks

TypeNameUpside
StockOramed Pharmaceuticals-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.36$2.36$2.36
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25------
Sep, 25------
Aug, 25------
Jul, 25------
Jun, 25------
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 12, 2023Canaccord GenuityHolddowngrade
May 16, 2022Aegis CapitalBuyBuyhold
Feb 18, 2022Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported--$-0.97$0.14----
Avg Forecast$-0.80$-0.80$-0.94$-0.32$-0.24$-0.12$-1.26$-0.82
High Forecast$-0.80$-0.80$-0.94$-0.21$1.02$-0.08$-1.26$-0.82
Low Forecast$-0.80$-0.80$-0.94$-0.41$-1.44$-0.16$-1.26$-0.82
Surprise %--3.19%-143.75%----

Revenue Forecast

$500K $1M $2M $3M $4M $5M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported--$2.70M$1.34M----
Avg Forecast$4.37M$2.92M$2.77M$1.32M$750.00K$1.00M$894.43K$781.68K
High Forecast$4.37M$2.92M$2.77M$1.34M$750.00K$1.00M$894.43K$781.68K
Low Forecast$4.37M$2.92M$2.77M$1.30M$750.00K$1.00M$894.43K$781.68K
Surprise %---2.33%1.52%----

Net Income Forecast

$-60M $-39M $-18M $3M $24M $45M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported--$-37.76M$5.53M----
Avg Forecast$-31.07M$-31.35M$-37.97M$-12.58M$4.46M$-4.87M$-51.11M$-33.26M
High Forecast$-31.07M$-31.35M$-37.97M$-8.39M$41.38M$-3.07M$-51.11M$-33.26M
Low Forecast$-31.07M$-31.35M$-37.97M$-16.77M$-58.42M$-6.66M$-51.11M$-33.26M
Surprise %---0.54%-143.92%----

ORMP Forecast FAQ

Is Oramed Pharmaceuticals stock a buy?

Oramed Pharmaceuticals stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Oramed Pharmaceuticals is a favorable investment for most analysts.

What is Oramed Pharmaceuticals's price target?

Oramed Pharmaceuticals's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.36.

How does Oramed Pharmaceuticals stock forecast compare to its benchmarks?

Oramed Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is Oramed Pharmaceuticals’s EPS forecast?

Oramed Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.24, marking a -271.43% decrease from the reported $0.14 in 2023. Estimates for the following years are $-0.12 in 2025, $-1.26 in 2026, and $-0.82 in 2027.

What is Oramed Pharmaceuticals’s revenue forecast?

Oramed Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $750K, reflecting a -44.03% decrease from the reported $1.34M in 2023. The forecast for 2025 is $1M, followed by $894.43K for 2026, and $781.68K for 2027.

What is Oramed Pharmaceuticals’s net income forecast?

Oramed Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $4.46M, representing a -19.19% decrease from the reported $5.52M in 2023. Projections indicate $-4.868M in 2025, $-51.114M in 2026, and $-33.265M in 2027.